Health Care

Explore how Carlyle Group’s recent Medline share purchase signals confidence and strategic buying, and what it means for investors.

Discover how Sionna Therapeutics’ insider buying and selling signals confidence yet reveals market challenges, and what this means for investors and future growth.

Insider buying by Ligand Pharmaceuticals’ chief legal officer shows confidence in a high‑growth, hormone‑targeted biotech amid market volatility and strategic shelf‑offer funding plans.

CEO RSU grant signals confidence in Madrigal’s cardiovascular drug pipeline, hinting at future growth and potentially easing investor volatility.

Explore how General Counsel Kelley Shannon’s RSU grant and insider trade impact Madrigal Pharma’s equity strategy, talent retention, and growth outlook.

Schrodinger’s insider sales are rule‑based, tax‑driven trades—no market‑move—yet the company’s IP assets and niche pharma‑software niche offer a value entry for long‑term investors.

Krystal Biotech insider sales raise questions about funding, market‑access timing and competitive positioning in rare‑disease gene‑therapy—what investors need to know.

Revolution Medicines insider trades reveal a strategic shift: CEO sells for liquidity while CFO and others buy, suggesting confidence in an undervalued oncology pipeline.

Insightful insider activity: Carole Huntsman’s modest Madrigal Pharmaceuticals shares and RSU/option buys reveal confidence in long‑term value, not short‑term gains.

CEO CG Oncology buy shows insider confidence amid rising Nasdaq shares—learn how option exercises and insider moves signal future value for investors.